Navigation Links
Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
Date:6/14/2011

BALTIMORE, June 14, 2011 /PRNewswire/ -- Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that data from the Phase 2b trial of ARC-4558 for the treatment of pain associated with painful diabetic neuropathy (PDN) will be the subject of two poster presentations at upcoming medical meetings.  The first poster will be presented at the American Diabetes Association's 71st Scientific Sessions, June 24-28, 2011, in San Diego, California.  The second poster will be presented at the Peripheral Nerve Society 2011 Biennial Meeting, June 25-29, 2011, in Potomac, Maryland.  ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride for topical administration.  

Arcion previously announced positive top-line results from a Phase 2b double-blind, randomized, placebo-controlled clinical trial of ARC-4558 in adult patients with PDN. The U.S. Food and Drug Administration (FDA) granted Fast Track designation to ARC-4558 for the treatment of pain associated with PDN. The Company also held an End of Phase 2 meeting with the FDA and the ARC-4558 program is now poised to enter Phase 3 studies.

Abstract Information

Topical Clonidine for Treatment of Painful Diabetic Neuropathy: a Randomized Double Blind Phase IIb Clinical Trial
Meeting: American Diabetes Association's 71st Scientific Sessions
Presenter: James N. Campbell, M.D. and William Schmidt, Ph.D.
Session Day / Time: Saturday, June 25, 2011, 10:00 a.m. to 7:30 p.m.
Additional showing: The poster will also be part of the "Pharmacologic Treatment of Diabetes-Diabetes Complications" tour session on June 27, 2011, 12:00 p.m. to 1:00 p.m.

Response to Topical Capsaicin Correlates with the Efficacy of Topical Clonidine as a Treatment for Painful Diabetic Neuropathy (PDN)
Meeting: Peripheral Nerve Society 2011 Biennial Meeting
Presenter:  James N. Campbell, M.D.
Session Day / Time: Tuesday, June 28, 2011, 7:30 to 8:30 a.m. poster viewing and 3:15 – 4:30 p.m. poster walk-around

About ARC-4558

ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride (HCL) for topical administration to the painful area in order to manage the neuropathic pain associated with painful diabetic neuropathy (PDN).  Topical clonidine, through its agonist effects on (a2)-adrenergic receptors, is believed to reduce pain in PDN via local actions on the nociceptors that innervate the affected skin. Based on the results of clinical trials to-date, Arcion believes that ARC-4558 has a level of efficacy comparable to systemic therapies in the target population, but with substantially fewer side effects. The 0.1% gel formulation avoids the treatment area limitations and undesirable aesthetic and skin reaction issues associated with analgesic patches. Furthermore, the ARC-4558 gel has been shown to provide analgesia without numbing or anesthetizing the skin.

About Painful Diabetic Neuropathy (PDN)

Neuropathy is a common complication of diabetes mellitus. According to 2008 estimates by the Centers for Disease Control and Prevention, nearly 18 million people in the United States are diagnosed with diabetes. Given a conservative estimate that 15% of people with diabetes have painful neuropathies, approximately 2.7 million Americans experience PDN. Patients with PDN often experience debilitating pain symptoms that affect day-to-day functioning and quality of life.  How diabetes causes a length-dependent neuropathy is unknown.  Arcion believes the PDN market is highly under-served by existing products and that there is a strong scientific rationale for developing a topical treatment for PDN that delivers analgesia in a way that avoids systemic side effects.

About Arcion

Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.  www.arciontherapeutics.com


'/>"/>
SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index
2. Northwest Biotherapeutics Announces Change and Expansion of Management Team
3. Northwest Biotherapeutics Announces Series of Financing Arrangements
4. Healthpoint Biotherapeutics Acquires Regranex® Gel
5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
6. Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
7. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
8. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
9. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
10. Nile Therapeutics to Transition to OTCQB Marketplace
11. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 30, 2016 , ... Doctors in Italy say mesothelioma patients ... than patients with lower levels. Surviving Mesothelioma has just posted an article on the ... centers in Genoa and La Spezia, Italy tested the blood serum, tumors, and lung ...
(Date:5/31/2016)... ... 31, 2016 , ... The Academy of Model Aeronautics is thrilled to announce ... Memorial Day through Labor Day 2016. Bill Chaffee’s Boeing P-12B will be exhibited thanks ... Chaffee won first place for Senior Scale Model at the 1930 National Airplane Model ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Weeks after ... News in Phoenix, Dr. Michael Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand ... practice. The Wrist MRI machine is a state-of-the-art technology and only 1 of about ...
(Date:5/27/2016)... NC (PRWEB) , ... May 27, 2016 , ... Doctors ... analyzing dozens of studies on the BRCA-1 associated protein (BAP1) gene and its link ... the website. Click here to read the full article now. , The ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):